Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol 20060 (PCYC): A Multicenter, Open-Label Pilot Study of Follicular Lymphoma Ibrutinib Consolidation for FDG-PET Positivity After Frontline Chemoimmunotherapy (FLIPP)

NCT02966730 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT02966730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02966730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol 20060 (PCYC): A Multicenter, Open-Label Pilot Study of Follicular Lymphoma Ibrutinib Consolidation for FDG-PET Positivity After Frontline Chemoimmunotherapy (FLIPP)
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
November 30, 2016
Completion date
June 20, 2019
Enrollment
2 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, follicular lymphoma grade iiia, follicular lymphoma, grade 1, follicular lymphoma, grade 2